With the recent creation of the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine in Baltimore, Maryland, we must remember that, while industrialized medicine has never attempted to serve all people, institutional histories vary from one organization to the next.

If we truly believe in the positive transformational power of visionary plant experiences, we must support each other to make real social change happen, less this transformation stagnates at the individual level.

After the murder of a Peruvian healer in 2018, traditional healers, local political figures, and nonprofit allies gathered to address the complexities that come with the influx of foreigners seeking ayahuasca in the Amazon.

Eight staff have quit The Third Wave and issued an open statement.

The Multidisciplinary Association for Psychedelic Studies (MAPS) submitted their MDMA PTSD expanded access protocol to the FDA on January 14, 2019.

As psychedelic medicalization and the potential profits of a “virgin market” loom large, new organizations are increasingly looking to gain legitimacy within the field. Mainstreaming means the doors of this field are being thrown wide open.

Until MDMA-assisted psychotherapy is proven without a doubt to reduce long-term costs, many insurance companies do not have an incentive to cover it.

What does MDMA rescheduling mean for the recreational user? If you are under the impression that MDMA is on its way to being rescheduled, across the board, you may be disappointed.

What does the future hold for MDMA? We explore MAPS' ongoing FDA phase 3 clinical trials, rescheduling, health insurance, and expanded access. 

Comedian Shane Mauss and Zendo Project's Ryan Beauregard on psychedelic-induced psychosis. “It was really easy once I got past the big video game, ‘Truman Show’ feeling, to get to a place of, ‘oh, that was all in my head. I was crazy.’"

The controlled narrative goes something like this: ayahuasca is good, and we need to control how people perceive it because this is a controlled substance we want to see legalized, a medicine we want to see legitimated. And if we have to sacrifice a few women who get themselves raped to keep ayahuasca’s name clean, so be it.

A few years ago, I witnessed the systematic silencing and shaming of Lily Kay Ross for having dared to call attention to severe abuses of power in the psychedelic space. Her extraordinary bravery in sharing her own experience with abuse was met with victim blaming and accusations of selfishness. Key members of the psychedelic research community turned on her for “jeopardizing” the entire field of psychedelic science with her “negativity” and “theatrics.”

Consent is really pretty simple but also apparently complicated, due to our inheritance of a messed up culture.

The research team at UConn studying MDMA-assisted psychotherapy for PTSD is now defunct.

psychedelic.support could soon become a useful asset to anyone interested in the professional world of psychedelic-related therapy.

As venture-capital-backed, for-profit companies barrel into psychedelic therapy, the potential for the widespread privatization of psychedelic knowledge and profits looms large. Some researchers are so enthusiastic about medicalization by “any means necessary” that they’re resorting to prohibitionist historical narratives and calling for monopolies to push the agenda forward.

We talked with Johns Hopkins psychedelic researcher, Alan Kooi Davis, about the Source Research Foundation, a non-profit awarding grants to students researching psychedelics.

What’s it like being sentenced to life in prison for selling LSD? Timothy Tyler, a Deadhead convicted of selling LSD and granted clemency by President Barack Obama, talked to Psymposia about his 26 years in prison, and the challenges of adjusting to a brave, new world.

Narratives which gloss-over the history and socioeconomic dynamics of ayahuasca’s globalization may, despite good intentions, actually do more harm than good.

Four years since that trip, I’m no longer prescribed antidepressants.